Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that ...

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.

Blood enters the left ventricle through the mitral valve and leaves through the aortic valve. A stenotic valve is a valve opening that has gotten smaller and is partially obstructing blood flow. In ...

Aortic stenosis is a serious heart valve condition characterized by narrowing and stiffening of the aortic valve, restricting blood flow from the heart to the body. This forces the heart to work ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

The timing of aortic valve replacement (AVR) in asymptomatic patients with severe aortic stenosis has been debated for several decades. Based on observational data and expert opinion, international ...

Rheumatic fever, which was once much more common in childhood than it is today, can damage your aortic valve. It is the most common cause of serious aortic valve regurgitation among older adults.